Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase I/II Study of GSK2110183 in Combination With Carboplatin and Paclitaxel in Subjects With Platinum-Resistant Ovarian Cancer

NCT01653912 is registered in ClinicalTrials.gov with Accenture as lead sponsor.

NCT NCT01653912
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01653912 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase I/II Study of GSK2110183 in Combination With Carboplatin and Paclitaxel in Subjects With Platinum-Resistant Ovarian Cancer
Lead sponsor
Accenture
Phase
Phase 1/2
Overall status
Completed
Start date
November 30, 2012
Completion date
November 30, 2015
Enrollment
59 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent platinum-resistant ovarian cancer